Beta Drugs Complete Financial Statements

In FY2025, Beta Drugs (BETA) reported revenue ₹106 Cr, net profit ₹12 Cr and EPS ₹12.10, with a net profit margin of 11.3% and ROE of 6.1%. Full financial statements from FY2018 to FY2025 (8 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see BETA share price.

8 Years of Data
2025 - 2018

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 11.32% 2025 data
EBITDA Margin 22.64% 2025 data
Operating Margin 21.00% 2025 data
Return on Assets 2.75% 2025 data
Return on Equity 6.09% 2025 data

Balance Sheet Ratios

Current Ratio 2.43 2025 data
Equity Ratio 45.18% 2025 data
Asset Turnover 0.24 2025 data

BETA Revenue, Net Profit & EBITDA — Year-on-Year Growth

BETA YoY (Dec 2024 vs Sept 2025) — revenue +19.1%, net profit +33.3%, EBITDA +41.2%, expenses +13.9%.

Revenue Growth
+19.1%
Year-over-Year
Net Profit Growth
+33.3%
Year-over-Year
EBITDA Growth
+41.2%
Year-over-Year
Expense Growth
+13.9%
Year-over-Year
Assets Growth
+71.7%
Year-over-Year
Equity Growth
+25.5%
Year-over-Year
Operating Cash Flow Growth
+16.1%
Year-over-Year
Investing Cash Flow Growth
-157.1%
Year-over-Year
Financing Cash Flow Growth
+1575.0%
Year-over-Year

BETA Income Statement — Revenue, EBITDA & Net Profit

Beta Drugs revenue ₹106 Cr, EBITDA ₹24 Cr, net profit ₹12 Cr, EPS ₹12.10 (2025) — net profit margin 11.3%. Explore BETA fundamental worth to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Dec 2024
Revenue 106 98 103 90 89
Expenses 82 79 81 70 72
EBITDA 24 19 23 19 17
Operating Profit Margin % 21.00% 16.00% 20.00% 19.00% 18.00%
Depreciation 4 4 4 4 3
Interest 4 3 3 4 2
Profit Before Tax 16 12 16 11 12
Tax 4 3 4 2 3
Net Profit 12 9 12 9 9
Earnings Per Share (₹) 12.10 8.95 11.59 8.40 9.31

BETA Balance Sheet — Assets, Liabilities & Shareholders' Equity

BETA total assets ₹436 Cr, total equity ₹197 Cr, total liabilities ₹ Cr (2025) — ROE 6.1%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018
ASSETS
Total Assets 436 254 198 158 118 107 83 50
Current Assets 331 178 128 97 68 56 43 32
Fixed Assets 89 65 63 55 40 44 18 13
Capital Work in Progress 0 0 0 0 3 0 15 1
Investments 0 0 0 0 0 0 0 0
Other Assets 347 190 136 103 75 63 50 35
LIABILITIES
Total Liabilities
Current Liabilities 136 12 13 17 16 13 9 3
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 197 157 123 92 69 57 41 33
Share Capital 10 10 10 10 10 10 9 9
Reserves & Surplus 187 148 113 83 59 48 32 24

BETA Cash Flow Statement — Operating, Investing & Financing

Beta Drugs operating cash flow ₹36 Cr, investing ₹-36 Cr, financing ₹118 Cr, net cash flow ₹118 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018
Operating Activities 36 31 23 30 19 8 0 17
Investing Activities -36 -14 -19 -22 -6 -15 -21 -11
Financing Activities 118 -8 -3 -1 -8 9 12 5
Net Cash Flow 118 10 2 7 5 2 -9 12